A Phase 2, Multi-Center, Randomized, Double-Masked, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects With Diabetic Macular Edema [INFINITY]
Latest Information Update: 10 Aug 2023
At a glance
- Drugs Ixoberogene soroparvovec (Primary) ; Aflibercept
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms INFINITY
- Sponsors Adverum Biotechnologies
Most Recent Events
- 06 Aug 2023 Status changed from active, no longer recruiting to completed.
- 04 Nov 2021 According to an Adverum Biotechnologies media release, data from this study will be presentation at the American Academy of Ophthalmology Annual Meeting (AAO 2021), November 12-15, 2021.
- 04 Nov 2021 According to an Adverum Biotechnologies media release, data from the trial were presented at the American Society of Retina Specialists (ASRS) 39th Annual Scientific Meeting, 2021.